National Bank of Canada
TRIB

National Bank of Canada’s Trinity Biotech TRIB Stock Holding History

National Bank of Canada’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Hold
0
– -$791 – 3201
2025
Q4 		– Hold
0
– – – 2649

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.72B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

National Bank of Canada's TRIB Position: Q1 2026 in Review

National Bank of Canada sold out of Trinity Biotech (TRIB) in Q1 2026, closing a stake of 33 shares — an estimated $791 sold.

National Bank of Canada first reported a position in TRIB in Q4 2025 and held it in 1 quarter. The position peaked at $791 in Q4 2025. 21 funds tracked by Wall St. Rank hold TRIB as of Q1 2026.

  • National Bank of Canada reported no remaining Trinity Biotech position as of Q1 2026 after selling out during the quarter.
  • National Bank of Canada sold 33 Trinity Biotech shares in Q1 2026, an estimated $791.
  • National Bank of Canada first reported a position in Trinity Biotech in Q4 2025 and held it in 1 quarter.
  • National Bank of Canada's Trinity Biotech position peaked at $791 in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.